Abstract
Herba Epimedii (HEP) known as YinYangHuo in Chinese is the dried leaf of the Epimediium, and has been historically used in combination with other herbs to treat skeletal diseases in traditional Chinese medicine (TCM). Here, we review the historical TCM interpretation of the action of HEP, its use in clinical trials, its main phytochemical constituents and its pharmacological findings. 85 clinical trials were identified which used HEP in TCM prescriptions with other herbs to treat primary and secondary osteoporosis from 2005 to now. More than 60 individual compounds were isolated and characterized from HEP and studied in various animal and cell models. HEP and its constituents exhibited a variety of anti-resorptive and bone formation-stimulating effects, which target different pathways in the bone remodeling cycle. These compounds may provide new perspectives in alternative treatment regimes and reveal novel chemical scaffolds for the development of anti-osteoporotic drugs. These approaches are also useful for guiding our research to employ an integrative therapeutic approach to treat complex diseases such as osteoporosis diseases which could be superior to the conventional single target – single drug approach.
Keywords: Herba epimedii, Chinese medicine, clinical trials, phytochemistry, pharmacology, osteoporosis.
Current Pharmaceutical Design
Title:Herba Epimedii: An Ancient Chinese Herbal Medicine in the Prevention and Treatment of Osteoporosis
Volume: 22 Issue: 3
Author(s): Lili Wang, Yu Li, Yubo Guo, Rufeng Ma, Min Fu, Jianzhao Niu, Sihua Gao and Dongwei Zhang
Affiliation:
Keywords: Herba epimedii, Chinese medicine, clinical trials, phytochemistry, pharmacology, osteoporosis.
Abstract: Herba Epimedii (HEP) known as YinYangHuo in Chinese is the dried leaf of the Epimediium, and has been historically used in combination with other herbs to treat skeletal diseases in traditional Chinese medicine (TCM). Here, we review the historical TCM interpretation of the action of HEP, its use in clinical trials, its main phytochemical constituents and its pharmacological findings. 85 clinical trials were identified which used HEP in TCM prescriptions with other herbs to treat primary and secondary osteoporosis from 2005 to now. More than 60 individual compounds were isolated and characterized from HEP and studied in various animal and cell models. HEP and its constituents exhibited a variety of anti-resorptive and bone formation-stimulating effects, which target different pathways in the bone remodeling cycle. These compounds may provide new perspectives in alternative treatment regimes and reveal novel chemical scaffolds for the development of anti-osteoporotic drugs. These approaches are also useful for guiding our research to employ an integrative therapeutic approach to treat complex diseases such as osteoporosis diseases which could be superior to the conventional single target – single drug approach.
Export Options
About this article
Cite this article as:
Wang Lili, Li Yu, Guo Yubo, Ma Rufeng, Fu Min, Niu Jianzhao, Gao Sihua and Zhang Dongwei, Herba Epimedii: An Ancient Chinese Herbal Medicine in the Prevention and Treatment of Osteoporosis, Current Pharmaceutical Design 2016; 22 (3) . https://dx.doi.org/10.2174/1381612822666151112145907
DOI https://dx.doi.org/10.2174/1381612822666151112145907 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Activated T Lymphocytes in Type 2 Diabetes: Implications From in Vitro Studies
Current Drug Targets How Does Alternaria alternata-Derived Alternariol Affect Our Health?
Mini-Reviews in Organic Chemistry Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Acknowledgements to Reviewers
Current Diabetes Reviews Effectiveness of Nasal Continuous Positive Airway Pressure (CPAP) Therapy on Cardiovascular Outcomes in Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS)
Current Respiratory Medicine Reviews The Genetic Basis of Glucose Homeostasis
Current Diabetes Reviews ING Proteins as Potential Anticancer Drug Targets
Current Drug Targets Leaf Aqueous Extract of Argania spiniosa Exhibits Antihyperglycemic Effect in Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Applications of Induced Pluripotent Stem Cells in the Modeling of Human Inflammatory Bowel Diseases
Current Stem Cell Research & Therapy Markers of Arrhythmogenic Risk in Hypertensive Subjects
Current Pharmaceutical Design Advances in Research on Pharmacological Activities and Synthesis of Oleanolic Acid Derivatives at C-3 Position
The Natural Products Journal The Apoptotic Pathway as a Therapeutic Target in Sepsis
Current Drug Targets Activated Surfaces for Laser Desorption Mass Spectrometry: Application for Peptide and Protein Analysis
Current Pharmaceutical Design Immune-Neuroendocrine Interactions Involving Thymus and Pineal Gland in Stem Cell Therapy of Age-Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Inhibition of NF-kB Activation and Cytokines Production in THP-1 Monocytes by 2-Styrylchromones
Medicinal Chemistry Significance of Green Synthetic Chemistry from a Pharmaceutical Perspective
Current Pharmaceutical Design Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets Comparison of Hypoglycemic and Antioxidant Activities of the Compounds Isolated from Ficus hispida Linn. and Ficus pomifera Wall
The Natural Products Journal Pharmacophore, 3D-QSAR Models and Dynamic Simulation of 1,4-Benzothiazines for Colorectal Cancer Treatment
Combinatorial Chemistry & High Throughput Screening Exploring the Management of Statin Intolerant Patients: 2016 and Beyond
Current Vascular Pharmacology